Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Post-treatment symptomatic improvement of the eastern Indian ADHD probands is influenced by CYP2D6 genetic variations.

Drug metabolism and personalized therapy - 1 Mar 2023

Chatterjee Mahasweta, Saha Sharmistha, Maitra Subhamita, Ray Anirban, Sinha Swagata, Mukhopadhyay Kanchan

Abstract excerpt

OBJECTIVES: Symptomatic remediation from attention deficit hyperactivity disorder (ADHD)-associated traits is achieved by treatment with methylphenidate (MPH)/atomoxetine (ATX). We have analyzed the association of functional CYP2D6 variations, rs1065852, rs3892097, rs1135840, and rs1058164, with ADHD in the Indian subjects. METHODS: Subjects were recruited following the Diagnostic and Statistical Manual for...

Read the complete abstract on PubMed

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Attention Deficit Disorder with Hyperactivity
Share to Cytochrome P-450 CYP2D6
Share to Genetic Variation
Share to Methylphenidate
Share to Treatment Outcome

Source

Identifiers

PMID: 36169235
DOI: 10.1515/dmpt-2022-0120

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Post-treatment symptomatic improvement of the eastern Indian ADHD probands is influenced by CYP2D6 genetic variations.PMID 36169235Read ↗

Dopamine Transporter and CYP2D6 Gene Relationships with Attention-Deficit/Hyperactivity Disorder Treatment Response in the Methylphenidate and Atomoxetine Crossover Study.Semantic proximity Read ↗

Pharmacogenetics predictors of methylphenidate efficacy in childhood ADHD.Semantic proximity Read ↗

Attention-deficit hyperactivity disorder in adults: A systematic review and meta-analysis of genetic, pharmacogenetic and biochemical studies.Semantic proximity Read ↗

Attention-deficit/hyperactivity disorder pharmacogenomics.Semantic proximity Read ↗

Pharmacogenetic Approach for a Better Drug Treatment in ChildrenSemantic proximity Read ↗

Association analysis of norepinephrine transporter polymorphisms and methylphenidate response in ADHD patients.Semantic proximity Read ↗

ADHD pharmacogenetics across the life cycle: New findings and perspectivesSemantic proximity Read ↗

Evaluation of SLCA62 and CYP2D6 Polymorphisms’ Effects on Atomoxetine Treatment in Attention Deficit and Hyperactivity DisorderSemantic proximity Read ↗

Evaluation of SLC6A2 and CYP2D6 polymorphisms' effects on atomoxetine treatment in attention deficit and hyperactivity disorder.Semantic proximity Read ↗

Molecular Profiling of Genes Associated With Methylphenidate Pathway Therapy and Discovery of New Variants in Amazonian Amerindian Populations.Semantic proximity Read ↗

Pharmacogenetics of methylphenidate response and tolerability in attention-deficit/hyperactivity disorder.Semantic proximity Read ↗

A candidate gene investigation of methylphenidate response in adult attention-deficit/hyperactivity disorder patients: results from a naturalistic study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.